以趋化因子受体为靶点的抗哮喘小分子药物研究进展

Advances in the study of small molecule antagonists of chemokine receptors as anti-asthma agents

哮喘是一种以气道炎症、气道高反应性及气道重塑为特征并伴随支气管炎性细胞浸润的慢性呼吸道疾病。趋化因子通过与趋化因子受体结合介导炎性细胞向支气管迁移,在哮喘发病中起着重要的作用。以趋化因子及其受体为靶点是目前抗炎、抗哮喘药物研究的热点。本文主要针对近年来趋化因子受体的小分子拮抗剂在抗哮喘方面的研究成果予以综述,将有助于抗哮喘药物设计,为进一步研究提供参考。

Asthma is a chronic inflammatory respiratory disease accompanied with airway inflammation,airway remodeling and bronchial hyperresponsiveness.Chemokines are important for the recruitment of immune cells to the lung,which play an important role in the formation and development of asthma.Targeting the chemokine receptors to anti-inflammation and anti-asthma is a new strategy and some candidate drugs are discovered recently.This review is focused on the development of chemokine receptor antagonists for anti-asthma,which will promote the compound designations.